Drug Shortage Report for CISPLATIN INJECTION

Last updated on 2020-05-29 History
Report ID 98188
Drug Identification Number 02403188
Brand name CISPLATIN INJECTION
Common or Proper name CISPLATIN INJECTION
Company Name TEVA CANADA LIMITED
Market Status MARKETED
Active Ingredient(s) CISPLATIN
Strength(s) 1.0MG
Dosage form(s) SOLUTION
Route of administration INTRAVENOUS
Packaging size 50 & 100ml
ATC code L01XA
ATC description OTHER ANTINEOPLASTIC AGENTS
Reason for shortage Demand increase for the drug.
Anticipated start date
Actual start date 2019-11-07
Estimated end date 2020-09-30
Actual end date 2020-05-27
Shortage status Resolved
Updated date 2020-05-29
Company comments Teva is allocating and covering 30% of the market
Health Canada comments
Contact Address 30 NOVOPHARM COURT
TORONTO, ONTARIO
CANADA M1B 2K9
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v11 2020-05-29 French Compare
v10 2020-05-29 English Compare
v9 2020-04-09 French Compare
v8 2020-04-09 English Compare
v7 2020-03-19 French Compare
v6 2020-03-19 English Compare
v5 2019-11-29 French Compare
v4 2019-11-29 English Compare
v3 2019-11-08 English Compare
v2 2019-11-07 French Compare
v1 2019-11-07 English Compare